- Home
- LILAK vs VCEL Comparison
LILAK vs VCEL Comparison
Compare LILAK & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILAK | VCEL |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | LILAK | VCEL |
|---|---|---|
| Price | $7.77 | $32.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $8.20 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 884.7K | 446.2K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $1.37 | $19.09 |
| Revenue Next Year | N/A | $17.96 |
| P/E Ratio | ★ N/A | $100.34 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $4.23 | $29.24 |
| 52 Week High | $9.13 | $48.75 |
Technical Indicators
Market Signals| Indicator | LILAK | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 34.04 |
| Support Level | $7.60 | $31.34 |
| Resistance Level | $8.44 | $38.48 |
| Average True Range (ATR) | 0.30 | 1.41 |
| MACD | -0.05 | -0.37 |
| Stochastic Oscillator | 44.50 | 15.85 |
Price Performance
Historical ComparisonAbout LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.